Brief: CSL Limited Enters Exclusive Agreement With Alentis Therapeutics
04/10/2026 23:46
BRIEF-CSL Limited Enters Exclusive Agreement With Alentis Therapeutics Oct 5 (Reuters) - CSL Limited CSL.AX:
CSL ENTERS EXCLUSIVE AGREEMENT WITH ALENTIS THERAPEUTICS
TO PAY ALENTIS $355 MILLION UPFRONT AND UP TO $1.2 BILLION IN MILESTONES
ENTERS AGREEMENT WITH ALENTIS TO CO-DEVELOP AND CO-PROMOTE LIXUDEBART
TO FULLY FUND PHASE 2 AND PHASE 3 TRIALS FOR LIXUDEBART
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSL
See all newsCiti says CSL's CEO pick brings key strengths
Australia's CSL names GSK executive Waterhouse as next CEO (updated)
Brief: CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director
Australia's CSL appoints Deborah Waterhouse as CEO
Early US flu season, current strain may signal risk for younger people; doctors urge shots